

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) An RNA capable of suppressing the expression of KLF5 gene, which comprises a sequence consisting of 15 to 30 contiguous nucleotides of KLF5 mRNA and a sequence complementary to the sequence.
2. (Original) The RNA according to claim 1, wherein the KLF5 mRNA is human KLF5 mRNA or mouse KLF5 mRNA.
3. (Currently Amended) The RNA according to claim 1 ~~or~~ 2, wherein the RNA is a double-stranded RNA consisting of a strand of a sequence consisting of 15 to 30 contiguous nucleotides of KLF5 mRNA and a strand of a sequence complementary to the sequence, in which 1 to 6 nucleotides are added to the 3'-terminus of each of the strands.
4. (Currently Amended) The RNA according to claim 1 ~~or~~ 2, wherein the RNA is an RNA forming a hairpin structure, which is obtained by ligating an

RNA having a sequence consisting of 15 to 30 contiguous nucleotides of the KLF5 mRNA to an RNA having a sequence complementary to the sequence via a spacer oligonucleotide, and then adding 1 to 6 nucleotides to the 3'-terminus thereof.

5. (Original) An RNA capable of suppressing the expression of KLF5 gene, which is selected from the group consisting of the following (a) to (c):
- (a) a double-stranded RNA having a strand of a sequence shown in any one of SEQ ID NOS: 2 to 16 and a strand of a sequence complementary to the sequence, in which 2 to 4 uridylic acids or deoxythymidylic acids are added to the 3'-terminus of each of the strands;
  - (b) an RNA forming a hairpin structure, which is obtained by ligating an RNA having a sequence shown in any one of SEQ ID NOS: 2 to 16 to an RNA having a sequence complementary to the sequence via spacer oligonucleotide that has 2 uridylic acids or deoxythymidylic acids at the 5'-terminus thereof, and then adding 2 to 4 uridylic acids or deoxythymidylic acids to the 3'-terminus thereof; and
  - (c) a double-stranded RNA consisting of a strand of a sequence shown in any one of SEQ ID NOS: 2 to 11 and a strand of a sequence complementary to the sequence, in which 2 uridylic acids are added to the 3'-terminus of each of the strands.

6. (Currently Amended) A vector, which allows the RNA according to claim 1 ~~any one of claims 1 to 5~~ to be expressed.

7. (Currently Amended) A method of suppressing the expression of KLF5 gene in cells by transfecting the RNA according to claim 1 ~~any one of claims 1 to 5 or the vector according to claim 6~~ into the cells.

8. (Currently Amended) A method of suppressing the expression of a gene whose transcription is activated by KLF5 in cells by transfecting the RNA according to claim 1 ~~any one of claims 1 to 5 or the vector according to claim 6~~ into the cells.

9. (Original) The method according to claim 8, wherein the gene whose transcription is activated by KLF5 is platelet-derived growth factor A chain gene or a smooth muscle myosin heavy chain SMemb gene.

10. (Currently Amended) A pharmaceutical composition, which comprises, as an active ingredient, the RNA according to claim 1 ~~any one of claims 1 to 5 or the vector according to claim 6~~.

11. (Currently Amended) A pharmaceutical composition for inhibiting angiogenesis, which comprises, as an active ingredient, the RNA according to claim 1 ~~any one of claims 1 to 5 or the vector according to claim 6~~.

12. (Currently Amended) A therapeutic or preventive agent for cardiovascular disease or cancer, which comprises, as an active ingredient, the RNA according to claim 1 ~~any one of claims 1 to 5 or the vector according to claim 6.~~

13. (Original) The therapeutic or preventive agent according to claim 12, wherein the cardiovascular disease is arteriosclerosis, restenosis occurring after coronary intervention, or cardiac hypertrophy.

14. (New) A method of suppressing the expression of KLF5 gene in cells by transfecting the vector according to claim 6 into the cells.

15. (New) A method of suppressing the expression of a gene whose transcription is activated by KLF5 in cells by transfecting the vector according to claim 6 into the cells.

16. (New) A pharmaceutical composition, which comprises, as an active ingredient, the vector according to claim 6.

17. (New) A pharmaceutical composition for inhibiting angiogenesis, which comprises, as an active ingredient, the vector according to claim 6.

18. (New) A therapeutic or preventive agent for cardiovascular disease or cancer, which comprises, as an active ingredient, the vector according to claim 6.